<DOC>
	<DOCNO>NCT03031782</DOCNO>
	<brief_summary>This double-blind , placebo-controlled , event-driven randomize withdrawal study investigate efficacy safety secukinumab treatment Juvenile Idiopathic Arthritis ( JIA ) category Juvenile Psoriatic Arthritis ( JPsA ) Enthesitis-related Arthritis ( ERA ) . The study divide 3 part ( plus post-treatment follow-up period ) consist open-label , single-arm active treatment Treatment Periods 1 3 randomize , double-blind , placebo control , event-driven withdrawal design Treatment Period 2 .</brief_summary>
	<brief_title>Secukinumab Safety Efficacy JPsA ERA</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Confirmed diagnosis Enthesitisrelated arthritis ( ERA ) Juvenile psoriatic arthritis ( JPsA ) accord International League Associations Rheumatology ( ILAR ) classification criterion least 6 month duration . 2 . Active disease ( ERA JPsA ) define : least 3 active joint least 1 site active enthesitis baseline document history . 3 . Inadequate response ( least 1 month ) intolerance least 1 nonsteroidal antiinflammatory drug ( NSAID ) 4 . Inadequate response ( least 2 month ) intolerance least 1 Diseasemodifying antirheumatic drug ( DMARD ) 5 . No concomitant use second line agent diseasemodifying and/or immunosuppressive drug . 1 . Patients fulfil ILAR diagnostic JIA category ERA JPsA . 2 . Patients ever receive biologic immunomodulating agent 3 . Patients take nonbiologic DMARD except MTX ( sulfasalazine ERA patient ) . 4 . Patients active uncontrolled inflammatory bowel disease active uncontrolled uveitis . Other protocoldefined inclusion/exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>JIA , JPsA , ERA , Secukinumab , ILAR</keyword>
</DOC>